AstraZeneca PLC
AZN
$171.34
-$1.96-1.13%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.63% | -1.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.63% | -1.39% | |||
| Cost of Revenue | -5.31% | -15.68% | |||
| Gross Profit | 1.89% | 2.29% | |||
| SG&A Expenses | 13.87% | -5.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 1.94% | -392.45% | |||
| Total Operating Expenses | 6.89% | -9.38% | |||
| Operating Income | -15.52% | 27.64% | |||
| Income Before Tax | -28.49% | 48.88% | |||
| Income Tax Expenses | -65.07% | 177.67% | |||
| Earnings from Continuing Operations | -18.60% | 32.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | 66.67% | |||
| Net Income | -18.60% | 32.42% | |||
| EBIT | -15.52% | 27.64% | |||
| EBITDA | -7.89% | 37.08% | |||
| EPS Basic | -18.71% | 32.59% | |||
| Normalized Basic EPS | -17.78% | 29.54% | |||
| EPS Diluted | -18.27% | 32.90% | |||
| Normalized Diluted EPS | -17.62% | 29.54% | |||
| Average Basic Shares Outstanding | 0.13% | -0.13% | |||
| Average Diluted Shares Outstanding | -0.06% | -0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -1.00% | -- | |||